>Other than defucosylation, do the GTC goats produce any additional changes in glycosylation pattern? Do the changes in glycosylation pattern affect the half-life of proteins produced by the GTC goats?<
GTC’s lead drug, ATryn, has a shorter half-life than plasma-derived antithrombin (#msg-11801772), and GTC thinks the shorter half-life is advantageous in the acute indications where ATryn will be used. However, the difference in half-life does not appear to be due to differences in glycosylation (#msg-11809654).
For GTC’s drug candidates in general, the company’s scientists believe that the transgenic platform will produce variants in glycosylation that have a therapeutic benefit, e.g. by enhancing ADCC in cancer mAbs. However, this remains to be demonstrated empirically. Regards, Dew
Market Data 
Markets 
AI
